sulforaphane

Phase 2Small molecule

EEastern Cooperative Oncology Group

sulforaphane is one of 606 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

605

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Depressive DisorderActive, not recruiting

Skin AgingActive, not recruiting

Bladder TumorActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Schizoaffective DisorderActive, not recruiting

Parkinson DiseaseActive, not recruiting

Kidney DiseaseActive, not recruiting

Autism Spectrum DisorderActive, not recruiting

Breast CancerActive, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

Depressive DisorderPhase 2

Active, not recruiting

Skin AgingPhase 1

Active, not recruiting

Bladder TumorPhase 2

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Schizoaffective DisorderPhase 2

Active, not recruiting

Parkinson DiseasePhase 2

Active, not recruiting

Kidney DiseasePhase 2

Active, not recruiting

Autism Spectrum DisorderPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

sulforaphane

EEastern Cooperative Oncology Group

Phase 2

18 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Lexiscan

Astellas

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 7

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 8

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 9

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 10

Iniparib

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Skin Aging

NCT03730649

Q2 2029

PreclinicalRecruiting

Anthracycline Related Cardiotoxicity in Breast Cancer

NCT03934905

Q3 2029

Phase 2Not yet recruiting

Melanoma

NCT07040280

Clinical

Trials by Indication[1]

Chronic Kidney Disease3 trials

Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease

Active, not recruiting·UUniversity of Rochester·Phase 2·NCT05653492·12 enrolled

Study of Sulphoraphane in Chronic Kidney Disease

Completed·UUniversity of Rochester·Phase 1·NCT05153174·18 enrolled

Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease

Active, not recruiting·UUniversity of Rochester·Phase 2·NCT05797506·100 enrolled

Skin Aging2 trials

Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure

Terminated·JJohns Hopkins University·Phase 2·NCT03126539·9 enrolled

Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure

Active, not recruiting·JJohns Hopkins University·Phase 1·NCT03730649·12 enrolled

Autism Spectrum Disorder2 trials

Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT02909959·48 enrolled

Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)

Completed·UUniversity of Massachusetts, Worcester·Phase 1/2·NCT02561481·60 enrolled

Cognitive Function1 trial

Effects of Sulforaphane on Cognitive Function in Patients With Frontal Brain Damage

Unknown status·XXiangya Hospital of Central South University·Phase 2·NCT04252261·90 enrolled

Schizophrenia1 trial

A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients

Completed·—·Phase 2·NCT04521868·125 enrolled

9 more indications

Depression1 trial

A 12-weeks Study to Evaluate Sulforaphane in the Treatment of Depression

Unknown status·—·Phase 2·NCT04246905·90 enrolled

Autism1 trial

Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism

Active, not recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT02677051·48 enrolled

Prostate Cancer1 trial

Sulforaphane in Treating Patients With Recurrent Prostate Cancer

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT01228084·20 enrolled

HIV1 trial

Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

Unknown status·SSunshine Specialty Health Care·Phase 4·NCT05224492·20 enrolled

Melanoma1 trial

Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma

Not yet recruiting·EEastern Cooperative Oncology Group·Phase 2·NCT07040280·120 enrolled

Type 2 Diabetes1 trial

Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes

Completed·—·Phase 2·NCT02801448·103 enrolled

Anthracycline Related Cardiotoxicity in Breast Cancer1 trial

Phase II Trial of Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction (CRI18-026)

Recruiting·TTexas Tech University Health Sciences Center·Preclinical·NCT03934905·70 enrolled

Diastolic Dysfunction1 trial

Prevention of Age-associated Cardiac and Vascular Dysfunction Through Nrf2 Signaling Using the Nutritional Supplement Sulforaphane

Withdrawn·TTexas Tech University Health Sciences Center·Preclinical·NCT05408559

Unspecified1 trial

A 6-month Study to Evaluate Sulforaphane Effects in PD Patients

Unknown status·—·Phase 2·NCT05084365·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for sulforaphane. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sulforaphane compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sulforaphane. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEastern Cooperative Oncology Group

sulforaphane

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2029

Q3 2029

Trials by Indication[1]

Chronic Kidney Disease3 trials

Skin Aging2 trials

Autism Spectrum Disorder2 trials

Cognitive Function1 trial

Schizophrenia1 trial

Depression1 trial

Autism1 trial

Prostate Cancer1 trial

HIV1 trial

Melanoma1 trial

Type 2 Diabetes1 trial

Anthracycline Related Cardiotoxicity in Breast Cancer1 trial

Diastolic Dysfunction1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News